KiSS-1 expression in human breast cancer.
Martin. Tracey A TA; Watkins. Gareth G; Jiang. Wen G WG
Key Findings
- KiSS-1 levels are higher in breast tumor tissue than in normal tissue.
- Higher KiSS-1 expression correlates with lymph‑node positivity, higher tumor grade, and higher TNM stage.
- Patients who died from breast cancer had higher KiSS-1 and lower KiSS-1 receptor levels.
- Introducing KiSS-1 into breast cancer cells increased their motility, invasiveness, and reduced adhesion.
Practical Outcomes
- For biohackers, this research suggests kisspeptin‑10 is not a beneficial supplement for health or longevity; instead, it appears to be a marker of aggressive breast cancer. There are no actionable dosing or protocol recommendations, and the peptide may even be harmful in the context of cancer. Focus should remain on well‑established health strategies rather than trying to modulate KiSS‑1.
Summary
The study found that higher levels of the peptide kisspeptin-10 (produced from the KiSS-1 gene) are linked to more aggressive breast cancers and worse patient outcomes, and that adding KiSS-1 to breast cancer cells makes them move and invade more.
Abstract
The KiSS-1 gene encodes a 145 amino acid residue peptide that is further processed to a final peptide, metastin, a ligand to a G-coupled orphan receptor (OT7T175/AXOR12). KiSS-1 has been identified as a putative human metastasis suppressor gene in melanomas and in breast cancer cell lines. This study aimed to determine the expression and distribution of KiSS-1 and its receptor in human breast cancer tissues and to identify a possible link between expression levels and patient prognosis. Frozen sections from breast cancer primary tumours (matched tumour 124 and background 33) were immuno-stained with KiSS-1 antibody. RNA was reverse transcribed and analyzed by Q-PCR (standardized using beta-actin, and normalized with cytokeratin-19 levels). Levels of expression of KiSS-1 were higher in tumour compared to background tissues (3,124+/-1,262 vs 2,397+/-1,181) and significantly increased in node positive tumours compared to node negative (3,637+/-1,719 vs 2,653+/-1,994, P = 0.02). KiSS-1 expression was also increased with increasing grade and TNM status. There were no such trends with the KiSS-1 receptor. Expression of KiSS-1 was higher in patients who had died from breast cancer than those who had remained healthy (4,631+/-3,024 vs 2,280+/-1,403) whereas expression of the receptor was reduced (480+/-162 vs 195+/-134). Immunohistochemical staining showed increased expression of KiSS-1 in tumour sections. Insertion of the KiSS-1 gene into the human breast cancer cell line MDA-MB-231, resulted in cells that were significantly more motile and invasive in behaviour, with reduced adhesion to matrix, using respective assays. In conclusion, KiSS-1 expression is increased in human breast cancer, particularly in patients with aggressive tumours and with mortality. Over-expression of KiSS-1 in breast cancer cells result in more aggressive phenotype. Together, it suggests that KiSS-1 plays a role beyond the initial metastasis repressor in this cancer type.
Study Information
pubmed
2005
10.1007/s10585-005-4180-0
112
32